Galectin Therapeutics to Discuss Belapectin at Nasdaq Event

Galectin Therapeutics will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024, to present its lead drug belapectin. The company's management team will hold one-on-one meetings and a fireside chat to discuss belapectin's potential in treating chronic liver disease and cancer.

author-image
Trim Correspondents
New Update
Galectin Therapeutics to Discuss Belapectin at Nasdaq Event

Galectin Therapeutics to Discuss Belapectin at Nasdaq Event

Galectin Therapeutics Inc. (NASDAQ: GALT), a leading developer of therapeutics targeting galectin proteins, announced that it will participate and present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will take place on May 20, 2024, at 4:00 PM ET at the Nasdaq World Headquarters in New York City.

Why this matters: The development of effective treatments for chronic liver disease and cancer has significant implications for public health, as these diseases are among the leading causes of morbidity and mortality worldwide. Advances in this area could lead to improved patient outcomes and reduced healthcare costs.

Galectin's management team will hold one-on-one meetings and a fireside chat at the conference to discuss the company's lead drug, belapectin. Belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The drug has shown promise in treating chronic liver disease and cancer.

Belapectin has received Fast Track designation from the U.S. Food and Drug Administration for its lead development program focused on metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer.

In addition to its MASH program, Galectin Therapeutics has additional development programs in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. However, the advancement of these additional clinical programs is largely dependent on finding a suitable partner.

Interested investors can access a webcast of the fireside chat on the Events & Presentation page of the investors section on Galectin's website. The company's management team will also be available for one-on-one meetings during the conference. Investors should contact their representative at H.C. Wainwright to arrange a meeting.

The upcoming event at Nasdaq World Headquarters provides an opportunity for Galectin Therapeutics to showcase the potential of belapectin in treating chronic liver disease and cancer to investors and stakeholders. With its Fast Track designation and promising results, belapectin represents a significant development in Galectin's mission to deliver novel therapies for patients in need.

Key Takeaways

  • Galectin Therapeutics to present at H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024.
  • Belapectin, a carbohydrate-based drug, shows promise in treating chronic liver disease and cancer.
  • Belapectin received Fast Track designation from FDA for metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis.
  • Galectin Therapeutics has additional development programs for combination immunotherapy for advanced head and neck cancers.
  • Investors can access a webcast of the fireside chat on Galectin's website and arrange one-on-one meetings during the conference.